THE BEST SIDE OF SEMAGLUTUDE WEEKS 13-16 BUNDLE

The demo obtained both its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically sizeable and excellent enhancements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH when compared with placebo.1Mounjaro will work to sc